Scholars Central

Conference abstract

Genetic modification of Francisella tularensis LVS for use as a novel live vaccine platform

Authors: Joseph Horzempa

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Francisella tularensis LVS is an attenuated bacterium that has been used as a live vaccine. Patients immunized with this organism show a very long-term memory response (over 30 years post vaccination) indicated by a strong cell-mediated immune response. Based on the fact that F. tularensis LVS is such a potent vaccine, we propose to use this organism as a novel vaccine platform. We have developed numerous molecular tools to modify the genome of F. tularensis and to facilitate exogenous gene expression including mutagenesis strategies and promoter identification. Interestingly, introducing attenuating mutations that enhance the stimulatory nature of LVS do not necessarily enhance this strain?s protective efficacy. Currently, licensed vaccines against important bacterial pathogens such as Pseudomonas aeruginosa and Staphylococcus aureus are not available. Because many pathogenic strains of these organisms are also drug resistant, the need for effective vaccines is magnified. Ongoing investigations involve engineering F. tularensis LVS to express genes encoding protective epitopes of either P. aeruginosa or S. aureus

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Vaccines & Vaccination
  • SubjectVaccines & Immunisation
  • BylineArticles whose byline prints “Joseph Horzempa”